Discussion stirs around TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) this week; here is what analysts are saying.

January 14, 2018 - By Michael Collier

 Discussion stirs around TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) this week; here is what analysts are saying.

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Ratings Coverage

Among 4 analysts covering Tracon Pharmaceuticals Inc (NASDAQ:TCON), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Tracon Pharmaceuticals Inc had 4 analyst reports since July 29, 2015 according to SRatingsIntel. TH Capital initiated TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) on Wednesday, July 29 with “Buy” rating. The firm has “Hold” rating by Zacks given on Friday, September 4. On Wednesday, July 29 the stock rating was initiated by Roth Capital with “Buy”. The firm has “Buy” rating given on Wednesday, December 21 by Jefferies. Below is a list of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) latest ratings and price target changes.

The stock decreased 9.37% or $0.3 during the last trading session, reaching $2.9. About 245,205 shares traded or 71.17% up from the average. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) has declined 52.06% since January 14, 2017 and is downtrending. It has underperformed by 68.76% the S&P500.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases. The company has market cap of $50.79 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. It currently has negative earnings. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

More notable recent TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news were published by: Seekingalpha.com which released: “TRACON Pharmaceuticals’ (TCON) CEO Charles Theuer on Q1 2017 Results …” on May 12, 2017, also Globenewswire.com with their article: “TRACON Pharmaceuticals to Present at Upcoming Investment Conferences” published on November 06, 2017, Globenewswire.com published: “TRACON Pharmaceuticals Announces Positive Results from National Cancer …” on August 16, 2017. More interesting news about TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) were released by: Marketwatch.com and their article: “TRACON Pharmaceuticals Inc.” published on January 30, 2015 as well as Globenewswire.com‘s news article titled: “TRACON Pharmaceuticals Announces TRC694 Data Presentation at Upcoming AACR …” with publication date: March 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.